Medicinova (MNOV) Change in Accured Expenses (2010 - 2025)
Medicinova (MNOV) posted quarterly Change in Accured Expenses of $582390.0 for Q4 2025, up 64.87% year-over-year from $353245.0 in Q4 2024, and up 256.57% quarter-over-quarter from $163331.0 in Q3 2025.
Medicinova (MNOV) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Medicinova (MNOV) has reported Change in Accured Expenses for 16 consecutive years, with $582390.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 64.87% year-over-year to $582390.0; the TTM figure through Dec 2025 stood at $459871.0 (up 247.23% YoY), while the FY2025 annual figure was $459871.0, up 247.23% from the prior year.
- Change in Accured Expenses climbed to $582390.0 in Q4 2025 per MNOV's latest filing, from $163331.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $844759.0 in Q2 2022 and bottomed at -$1.4 million in Q4 2021.
- Historically, Change in Accured Expenses has averaged -$26537.6 across 5 years, with a median of $79076.5 in 2021.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses slumped 512.43% — and 2025, when it surged 103870.22%.
- Medicinova's Change in Accured Expenses stood at -$1.4 million in 2021, then increased by 1.9% to -$1.3 million in 2022, then surged by 135.82% to $476913.0 in 2023, then retreated by 25.93% to $353245.0 in 2024, then surged by 64.87% to $582390.0 in 2025.
- Business Quant data shows MNOV's Change in Accured Expenses at $582390.0 in Q4 2025, $163331.0 in Q3 2025, and $527129.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Medicinova | 68.42 Mn | 68.42 Mn | 317,759.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 582,390.00 |
| Dec 31, 2025 | 582,390.00 |
| Sep 30, 2025 | 163,331.00 |
| Sep 30, 2025 | 163,331.00 |
| Jun 30, 2025 | 527,129.00 |
| Jun 30, 2025 | 527,129.00 |
| Mar 31, 2025 | -812,979.00 |
| Mar 31, 2025 | -812,979.00 |
| Dec 31, 2024 | 353,245.00 |
| Dec 31, 2024 | 353,245.00 |
| Sep 30, 2024 | 115,246.00 |
| Sep 30, 2024 | 115,246.00 |
| Jun 30, 2024 | 507.00 |
| Jun 30, 2024 | 507.00 |
| Mar 31, 2024 | -781,345.00 |
| Mar 31, 2024 | -781,345.00 |
| Dec 31, 2023 | 476,913.00 |
| Dec 31, 2023 | 476,913.00 |
| Sep 30, 2023 | -28,799.00 |
| Sep 30, 2023 | -28,799.00 |